Cingulate extends trial period for Chief Medical Officer Matthew Brams’ employment agreement to Dec. 31, 2026

• Cingulate entered an amendment to Executive Vice President and Chief Medical Officer Matthew N. Brams’ employment agreement, effective Jan. 1, 2026.
• The change extends the trial period for Brams’ full-time employment to Dec. 31, 2026 from Sept. 30, 2026.
• The amendment was executed on Sept. 30, 2026 through Cingulate Therapeutics, its wholly owned subsidiary.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045527), on October 02, 2026, and is solely responsible for the information contained therein.